Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/hospitalization 59% primary Improvement Relative Risk Death/hospitalization (b) 71% Mortality 15% unadjusted Ventilation 9% unadjusted Hospitalization 48% unadjusted Progression 42% unadjusted c19ivm.org de Jesús Ascencio-Montiel et al. Ivermectin EARLY Is early treatment with ivermectin+AZ, acetaminophen, aspirin beneficial for COVID-19? Retrospective 28,048 patients in Mexico Lower death/hosp. (p<0.0001) and hospitalization (p<0.0001) de Jesús Ascencio-Montiel et al., Archives of Me.., doi:10.1016/j.arcmed.2022.01.002 Favors ivermectin Favors control
A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
de Jesús Ascencio-Montiel et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002
de Jesús Ascencio-Montiel et al., A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19, Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 28,048 COVID+ patients in Mexico, 7,898 receiving a treatment kit including low dose ivermectin, AZ, aspirin, and acetaminophen, shower lower mortality/hospitalization for those receiving the kit. Delivery of the treatment kit was based on availability in the medical units. Adherence is unknown and may be low. Adjusted results are only provided for combined mortality/hospitalization.
risk of death/hospitalization, 59.0% lower, RR 0.41, p < 0.001, treatment 7,898, control 20,150, adjusted per study, multivariable, primary outcome.
risk of death/hospitalization, 71.0% lower, RR 0.29, p < 0.001, treatment 5,557, control 12,526, adjusted per study, with phone call followup, multivariable.
risk of death, 15.0% lower, RR 0.85, p = 0.16, treatment 101 of 7,898 (1.3%), control 303 of 20,150 (1.5%), NNT 445, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
risk of mechanical ventilation, 9.1% lower, RR 0.91, p = 0.51, treatment 77 of 7,898 (1.0%), control 216 of 20,150 (1.1%), NNT 1031, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
risk of hospitalization, 47.6% lower, RR 0.52, p < 0.001, treatment 485 of 7,898 (6.1%), control 2,360 of 20,150 (11.7%), NNT 18, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
risk of progression, 41.8% lower, RR 0.58, p < 0.001, treatment 435 of 7,898 (5.5%), control 1,906 of 20,150 (9.5%), NNT 25, unadjusted, ER, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
de Jesús Ascencio-Montiel et al., 24 Jan 2022, retrospective, Mexico, peer-reviewed, 10 authors, dosage 6mg days 1-2, this trial uses multiple treatments in the treatment arm (combined with AZ, acetaminophen, aspirin) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Journal Pre-proof A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19 Iván de Jesús Ascencio-Montiel , Juan Carlos Tomás-López , Verónica Álvarez-Medina , Luisa Estela Gil-Velázquez , Hortensia Vega-Vega , Héctor Raúl Vargas-Sánchez , Manuel Cervantes-Ocampo , Miguel Ángel Villası́s-Keever , Cesar Raúl González-Bonilla , Célida Duque-Molina PII: DOI: Reference: S0188-4409(22)00002-9 https://doi.org/10.1016/j.arcmed.2022.01.002 ARCMED 2717 To appear in: Archives of Medical Research Received date: Revised date: Accepted date: August 26, 2021 January 3, 2022 January 13, 2022 Please cite this article as: Iván de Jesús Ascencio-Montiel , Juan Carlos Tomás-López , Verónica Álvarez-Medina , Luisa Estela Gil-Velázquez , Hortensia Vega-Vega , Héctor Raúl Vargas-Sánchez , Manuel Cervantes-Ocampo , Miguel Ángel Villası́s-Keever , Cesar Raúl González-Bonilla , Célida Duque-Molina , A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19, Archives of Medical Research (2022), doi: https://doi.org/10.1016/j.arcmed.2022.01.002 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Inc. on behalf of Instituto Mexicano del Seguro Social (IMSS). Arch Med Res 21-01098 Archives of Medical Research 53 (2022) x–x ORIGINAL ARTICLE A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19 Iván de Jesús Ascencio-Montiel,a Juan Carlos Tomás-López,b Verónica Álvarez-Medina,b Luisa Estela Gil-Velázquez,b Hortensia VegaVega,b Héctor Raúl Vargas-Sánchez,b Manuel Cervantes-Ocampo,c Miguel Ángel Villasís-Keever,d Cesar Raúl González-Bonilla,d and Célida Duque-Molinaf a Coordinación de Vigilancia Epidemiológica, Unidad de Planeación e Innovación en Salud, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México b División de Medicina Familiar, Coordinación de Unidades de Primer Nivel, Unidad de Atención Médica, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México c Coordinación de Unidades de Primer Nivel, Unidad de Atención Médica, Dirección de Prestaciones Médicas Instituto Mexicano del Seguro Social, Ciudad de México, México d Unidad de Investigación en Análisis y Síntesis de la Evidencia, Coordinación de Investigación en Salud, Unidad de Educación e 1 Arch Med Res 21-01098 Investigación, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México e Coordinación de Investigación en Salud, Unidad de Educación e Investigación, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México f Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México Received for publication August 28, 2021; accepted January 13, 2022..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit